10-Q quarterly report · filed Nov 5, 2026

NOVAVAX INC (NVAX) Q3 2026 10-Q Quarterly Report

Short answer

NOVAVAX INC (NVAX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $68M (down 3.0% year over year) with net income of −$31M.

Q3 2026 key financials · XBRL

Revenue
$68M
−3.0% YoY · +20.5% QoQ
Net income
−$31M
+84.5% YoY · +41.2% QoQ
Operating margin
-45.8%
EPS (diluted)
−$0.19
+81.4% YoY · +40.6% QoQ

Source: XBRL data from the NOVAVAX INC (NVAX) Q3 2026 10-Q on SEC EDGAR. USD.

NOVAVAX INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $68.3M, down $2.1M YoY from $70.4M
  • Product sales $25.7M, up $12.3M YoY, driven by supply sales
  • Licensing revenue $42.6M, down $14.4M YoY, with Sanofi revenue down $29.5M
  • Net loss $31.4M vs $202.4M YoY, R&D expense $52.4M vs $98.3M
  • Cash, restricted cash and marketable securities $627.0M vs $750.5M at December 31; operating cash burn $199.5M through nine months

Risk Factors

  • New financing risk: February 2026 Credit Agreement added $50.0 million funded debt at 8.7% interest, secured by substantially all assets
  • Liquidity risk: Operating cash outflows reached $199.5 million for nine months, with cash and securities totaling $627.0 million
  • Regulatory and compliance risk: Australia APA exposure includes up to $92.5 million refundable if updated vaccine approval and delivery deadlines are missed
  • Operational risk: Reliance on Serum for COVID-19 vaccine co-formulation, filling, and finishing
  • Revenue concentration risk: Sanofi licensing revenue declined to $18.8 million from $48.3 million year over year

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other NOVAVAX INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.